Psyence Biomedical Ltd. Common Shares (PBM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has a cash flow conversion efficiency ratio of 0.060x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-662.00) by net assets ($-10.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Psyence Biomedical Ltd. Common Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PBM total debt and obligations for a breakdown of total debt and financial obligations.
Psyence Biomedical Ltd. Common Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capital Drilling Ltd
LSE:CAPD
|
0.156x |
|
KEY Petroleum Ltd
AU:KEY
|
-0.230x |
|
Softimat S.A.
BR:SOFT
|
-0.060x |
|
Ecobuilt Holdings Bhd
KLSE:0059
|
0.116x |
|
Mexican Gold Corp
V:MEX
|
0.953x |
|
Birddog Technology Ltd
AU:BDT
|
-0.302x |
|
Ordissimo
PA:ALORD
|
0.088x |
|
Tree House Education & Accessories Limited
NSE:TREEHOUSE
|
0.000x |
Annual Cash Flow Conversion Efficiency for Psyence Biomedical Ltd. Common Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Psyence Biomedical Ltd. Common Shares from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see PBM market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.72 Million | $-3.73 Million | -0.556x | -306.95% |
| 2024-03-31 | $-10.97 Million | $-2.95 Million | 0.268x | +12739.31% |
| 2023-03-31 | $244.66 Million | $-519.60K | -0.002x | +63.52% |
| 2022-03-31 | $239.84 Million | $-1.40 Million | -0.006x | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more